Page 834 - Read Online

Bhangui et al. Hepatoma Res 2020;6:71 I http://dx.doi.org/10.20517/2394-5079.2020.67 Page 13 of 15

4. Herrero JI, Sangro B, Quiroga J, Pardo F, Herraiz M, et al. Influence of tumor characteristics on the outcome of liver transplantation
among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001;7:631-6.
5. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, et al. Liver transplantation criteria for hepatocellular carcinoma should be
expanded. A 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502-11.
6. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, et al. Predicting survival after liver transplantation in patients with
hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
7. D’Amico F, Schwartz M, Vitale A, Tabrizian P, Roayaie S, et al. Predicting recurrence after liver transplantation in patients with
hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009;15:1278-87.
8. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis
2007;25:310-2.
9. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular
carcinoma at one large-volume center. Liver Transpl 2008;14:935-45.
10. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, et al; Liver Transplantation French Study Group. Liver transplantation
for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology
2012;143:986-94.
11. Kaido T, Ogawa K, Mori A, Fujimoto Y, Ito T, et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation
for hepatocellular carcinoma. Surgery 2013;154:1053-60.
12. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uchiyama H, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the
recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009;87:531-7.
13. Ito T, Takada Y, Ueda M, Haga H, Maetani Y, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living
donor liver transplantation. Liver Transpl 2007;13:1637-44.
14. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, et al. Recommendations for liver transplantation for hepatocellular carcinoma:
an international consensus conference report. Lancet Oncol 2012;13:e11-22.
15. Alshahrani AA, Ha SM, Hwang S, Ahn CS, Kim KH, et al. Clinical features and surveillance of very late hepatocellular carcinoma
recurrence after liver transplantation. Ann Transplant 2018;23:659-65.
16. Chok KS, Chan SC, Cheung TT, Chan AC, Fan ST, et al. Late recurrence of hepatocellular carcinoma after liver transplantation. World J
Surg 2011;35:2058-62.
17. Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, et al. Long-term observation of hepatocellular carcinoma
recurrence after liver transplantation at a European transplantation centre. United European Gastroenterol J 2019;7:838-49.
18. Soin AS, Bhangui P, Kataria T, Baijal SS, Piplani T, et al. Experience with LDLT in patients with hepatocellular carcinoma and portal
vein tumor thrombosis postdownstaging. Transplantation 2020; doi: 10.1097/TP.0000000000003162.
19. de’Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic
review. World J Gastroenterol 2015;21:11185-98.
20. Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, et al. Metroticket 2.0 model for analysis of competing risks of death after liver
transplantation for hepatocellular carcinoma. Gastroenterology 2018;154:128-39.
21. Liang W, Wu L, Ling X, Schroder PM, Ju W, et al. Living donor liver transplantation versus deceased donor liver transplantation for
hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012;18:1226-36.
22. Fernandez-Sevilla E, Allard MA, Selten J, Golse N, Vibert E, et al. Recurrence of hepatocellular carcinoma after liver transplantation: Is
there a place for resection? Liver Transpl 2017;23:440-7.
23. Sapisochin G, Goldaracena N, Astete S, Laurence JM, Davidson D, et al. Benefit of treating hepatocellular carcinoma recurrence after
liver transplantation and analysis of prognostic factors for survival in a large Euro-American series. Ann Surg Oncol 2015;22:2286-94.
24. Kornberg A, Küpper B, Tannapfel A, Katenkamp K, Thrum K, et al. Long-term survival after recurrent hepatocellular carcinoma in liver
transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol 2010;36:275-80.
25. Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, et al. Management of hepatocellular carcinoma recurrence after liver
transplantation. Transplant Proc 2010;42:660-2.
26. Escartin A, Sapisochin G, Bilbao I, Vilallonga R, Bueno J, et al. Recurrence of hepatocellular carcinoma after liver transplantation.
Transplant Proc 2007;39:2308-10.
27. Kim HR, Cheon SH, Rha SY, Lee S, Han KH, et al. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Asia Pac J
Clin Oncol 2011;7:258-69.
28. Wang Y, Speeg KV, Washburn WK, Halff G. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.
World J Gastroenterol 2010;16:5518-22.
29. Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, et al. Personalized molecular targeted therapy in advanced, recurrent
hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 2010;52:771-75.
30. Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, et al. Efficacy and safety of sorafenib in combination with
mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012;18:45-52.
31. Sposito C, Mariani L, Germini A, Reyes MF, Bongini M, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent
hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol 2013;59:59-66.
32. Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, et al. Sorafenib for recurrence of hepatocellular carcinoma after liver
transplantation. Dig Liver Dis 2012;44:432-37.
33. Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J